Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $181,097.40 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 7,590 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $23.86, for a total transaction of $181,097.40. Following the completion of the transaction, the insider owned 199,405 shares of the company’s stock, valued at approximately $4,757,803.30. The trade was a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

NASDAQ:KMTS opened at $25.06 on Thursday. Kestra Medical Technologies, Ltd. has a 12 month low of $14.10 and a 12 month high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The business’s 50-day moving average is $22.78 and its 200 day moving average is $22.52. The company has a market capitalization of $1.47 billion, a P/E ratio of -10.36 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The firm had revenue of $28.64 million for the quarter. On average, equities research analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System boosted its stake in Kestra Medical Technologies by 39.2% during the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after purchasing an additional 7,844 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after acquiring an additional 5,731 shares during the last quarter. Quantinno Capital Management LP acquired a new position in shares of Kestra Medical Technologies during the 1st quarter worth approximately $431,000. Sei Investments Co. grew its position in shares of Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after purchasing an additional 43,753 shares in the last quarter. Finally, Spartan Wealth Advisory Services LLC purchased a new position in Kestra Medical Technologies during the first quarter worth approximately $603,000.

Analyst Ratings Changes

KMTS has been the topic of several research analyst reports. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday, July 15th. Oppenheimer started coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. BTIG Research upped their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Finally, The Goldman Sachs Group reduced their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.83.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.